Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01695174

A Pilot Study of Xifaxan to Treat Patients With PSC — PSC  

Primary Sclerosing Cholangitis (PSC) Clinical Trial

Official title:
A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis

Clinical Trial Summary

In the current protocol, we propose the assessment of potential beneficial effects of the antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15 adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or equal to 40 kg will receive Xifaxan, 550 mg twice daily.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01695174
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 1
Start date August 2012
Completion date March 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT05082779 - Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 Phase 1
Completed NCT06037577 - Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Phase 1
Completed NCT01672853 - Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT02061540 - Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT01819766 - Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease N/A
Active, not recruiting NCT01161992 - Genomics of Primary Sclerosing Cholangitis (PSC)
Completed NCT02808312 - Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Phase 1
Completed NCT03333928 - A POC and Dose-Ranging Study of HTD1801 in PSC Patients Phase 2
Completed NCT02177136 - Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT03766035 - Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Recruiting NCT06026865 - S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC) N/A